Literature DB >> 22573529

Pathogenesis of calcineurin inhibitor-induced hypertension.

Ewout J Hoorn1, Stephen B Walsh, James A McCormick, Robert Zietse, Robert J Unwin, David H Ellison.   

Abstract

This article reviews the current understanding of the mechanisms of calcineurin inhibitor-induced hypertension. Already early after the introduction of cyclosporine in the 1980s, vasoconstriction, sympathetic excitation and sodium retention by the kidney had been shown to play a role in this form of hypertension. The vasoconstrictive effects of calcineurin inhibitors are related to interference with the balance of vasoactive substances, including endothelin and nitric oxide. Until recently, the renal site of the sodium-retaining effect of calcineurin inhibitors was unknown. We and others have shown that calcineurin inhibitors increase the activity of the thiazide-sensitive sodium chloride cotransporter through an effect on the kinases WNK and SPAK. Here, we review the pertinent literature on the hypertensinogenic effects of calcineurin inhibitors, including neural, vascular and renal effects, and we propose an integrated model of calcineurin inhibitor-induced hypertension.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22573529      PMCID: PMC4048819          DOI: 10.5301/jn.5000174

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  65 in total

1.  The acute effects of FK-506 on renal haemodynamics, water and sodium excretion and plasma levels of angiotensin II, aldosterone, atrial natriuretic peptide and vasopressin in pigs.

Authors:  K Golbaekdal; C B Nielsen; E B Pedersen
Journal:  J Pharm Pharmacol       Date:  1996-11       Impact factor: 3.765

2.  Cyclosporine A up-regulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells.

Authors:  P V Avdonin; F Cottet-Maire; G V Afanasjeva; S A Loktionova; P Lhote; U T Ruegg
Journal:  Kidney Int       Date:  1999-06       Impact factor: 10.612

Review 3.  Cyclosporine-induced hypertension after transplantation.

Authors:  S C Textor; V J Canzanello; S J Taler; D J Wilson; L L Schwartz; J E Augustine; J M Raymer; J C Romero; R H Wiesner; R A Krom
Journal:  Mayo Clin Proc       Date:  1994-12       Impact factor: 7.616

4.  Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantation.

Authors:  S C Textor; J C Burnett; J C Romero; V J Canzanello; S J Taler; R Wiesner; M Porayko; R Krom; G Gores; E Hay
Journal:  Kidney Int       Date:  1995-05       Impact factor: 10.612

5.  Role of angiotensin II and reactive oxygen species in cyclosporine A-dependent hypertension.

Authors:  Akira Nishiyama; Hiroyuki Kobori; Toshiki Fukui; Guo-Xing Zhang; Li Yao; Matlubur Rahman; Hirofumi Hitomi; Hideyasu Kiyomoto; Takatomi Shokoji; Shoji Kimura; Masakazu Kohno; Youichi Abe
Journal:  Hypertension       Date:  2003-07-21       Impact factor: 10.190

6.  Aldosterone resistance in kidney transplantation is in part induced by a down-regulation of mineralocorticoid receptor expression.

Authors:  P J Heering; C Kurschat; D T Vo; N Klein-Vehne; K Fehsel; K Ivens
Journal:  Clin Transplant       Date:  2004-04       Impact factor: 2.863

7.  The calcineurin inhibitor FK506 (tacrolimus) is associated with transient metabolic acidosis and altered expression of renal acid-base transport proteins.

Authors:  Nilufar Mohebbi; Marija Mihailova; Carsten A Wagner
Journal:  Am J Physiol Renal Physiol       Date:  2009-05-13

8.  Hypertension in cyclosporin A-treated patients is independent of circulating endothelin levels.

Authors:  T Forslund; P Hannonen; S Reitamo; F Fyhrquist
Journal:  J Intern Med       Date:  1995-07       Impact factor: 8.989

9.  Cyclosporin A inhibits nitric oxide synthase induction in vascular smooth muscle cells.

Authors:  T Marumo; T Nakaki; K Hishikawa; H Suzuki; R Kato; T Saruta
Journal:  Hypertension       Date:  1995-04       Impact factor: 10.190

10.  Oral cyclosporine but not tacrolimus reduces renal transplant blood flow.

Authors:  Brian J Nankivell; Jeremy R Chapman; George Bonovas; Simon M Gruenewald
Journal:  Transplantation       Date:  2004-05-15       Impact factor: 4.939

View more
  49 in total

1.  American Society of Nephrology Quiz and Questionnaire 2015: Electrolytes and Acid-Base Disorders.

Authors:  Mitchell H Rosner; Mark A Perazella; Michael J Choi
Journal:  Clin J Am Soc Nephrol       Date:  2016-01-29       Impact factor: 8.237

Review 2.  Comprehensive review of cardiovascular toxicity of drugs and related agents.

Authors:  Přemysl Mladěnka; Lenka Applová; Jiří Patočka; Vera Marisa Costa; Fernando Remiao; Jana Pourová; Aleš Mladěnka; Jana Karlíčková; Luděk Jahodář; Marie Vopršalová; Kurt J Varner; Martin Štěrba
Journal:  Med Res Rev       Date:  2018-01-05       Impact factor: 12.944

Review 3.  The sodium chloride cotransporter SLC12A3: new roles in sodium, potassium, and blood pressure regulation.

Authors:  Arthur D Moes; Nils van der Lubbe; Robert Zietse; Johannes Loffing; Ewout J Hoorn
Journal:  Pflugers Arch       Date:  2013-12-06       Impact factor: 3.657

4.  Renin-angiotensin system inhibitors in kidney transplantation: a benefit-risk assessment.

Authors:  Claudio Ponticelli; David Cucchiari
Journal:  J Nephrol       Date:  2017-02-17       Impact factor: 3.902

5.  Factors associated with cardiovascular target organ damage in children after renal transplantation.

Authors:  Bianca Borchert-Mörlins; Daniela Thurn; Bernhard M W Schmidt; Anja K Büscher; Jun Oh; Tanja Kier; Elena Bauer; Sabrina Baig; Nele Kanzelmeyer; Markus J Kemper; Rainer Büscher; Anette Melk
Journal:  Pediatr Nephrol       Date:  2017-08-13       Impact factor: 3.714

6.  Preventing Allograft Rejection by Targeting Immune Metabolism.

Authors:  Chen-Fang Lee; Ying-Chun Lo; Chih-Hsien Cheng; Georg J Furtmüller; Byoungchol Oh; Vinicius Andrade-Oliveira; Ajit G Thomas; Caitlyn E Bowman; Barbara S Slusher; Michael J Wolfgang; Gerald Brandacher; Jonathan D Powell
Journal:  Cell Rep       Date:  2015-10-17       Impact factor: 9.423

7.  Targeting the Trafficking of Kidney Water Channels for Therapeutic Benefit.

Authors:  Pui W Cheung; Richard Bouley; Dennis Brown
Journal:  Annu Rev Pharmacol Toxicol       Date:  2019-09-27       Impact factor: 13.820

8.  Calcineurin inhibitor cyclosporine A activates renal Na-K-Cl cotransporters via local and systemic mechanisms.

Authors:  K I Blankenstein; A Borschewski; R Labes; A Paliege; C Boldt; J A McCormick; D H Ellison; M Bader; S Bachmann; K Mutig
Journal:  Am J Physiol Renal Physiol       Date:  2016-12-21

9.  Adverse Events under Tacrolimus and Cyclosporine in the First 3 Years Post-Renal Transplantation in Children.

Authors:  Pauline Lancia; Beate Aurich; Phuong Ha; Anne Maisin; Véronique Baudouin; Evelyne Jacqz-Aigrain
Journal:  Clin Drug Investig       Date:  2018-02       Impact factor: 2.859

10.  Posttransplant metabolic syndrome in the withdrawal of immunosuppression in Pediatric Liver Transplant Recipients (WISP-R) pilot trial.

Authors:  E R Perito; S Mohammad; P Rosenthal; E M Alonso; U D Ekong; S J Lobritto; S Feng
Journal:  Am J Transplant       Date:  2015-02-03       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.